209 related articles for article (PubMed ID: 38732254)
1. Unraveling the Complexities of Toll-like Receptors: From Molecular Mechanisms to Clinical Applications.
Chen YH; Wu KH; Wu HP
Int J Mol Sci; 2024 May; 25(9):. PubMed ID: 38732254
[TBL] [Abstract][Full Text] [Related]
2. Toll-like receptors (TLRs) in cancer; with an extensive focus on TLR agonists and antagonists.
Keshavarz A; Pourbagheri-Sigaroodi A; Zafari P; Bagheri N; Ghaffari SH; Bashash D
IUBMB Life; 2021 Jan; 73(1):10-25. PubMed ID: 33217774
[TBL] [Abstract][Full Text] [Related]
3. Toll-like receptor-guided therapeutic intervention of human cancers: molecular and immunological perspectives.
Mukherjee S; Patra R; Behzadi P; Masotti A; Paolini A; Sarshar M
Front Immunol; 2023; 14():1244345. PubMed ID: 37822929
[TBL] [Abstract][Full Text] [Related]
4. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
5. Toll-Like Receptors (TLRs), NOD-Like Receptors (NLRs), and RIG-I-Like Receptors (RLRs) in Innate Immunity. TLRs, NLRs, and RLRs Ligands as Immunotherapeutic Agents for Hematopoietic Diseases.
Wicherska-Pawłowska K; Wróbel T; Rybka J
Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948194
[TBL] [Abstract][Full Text] [Related]
6. Application potential of toll-like receptors in cancer immunotherapy: Systematic review.
Shi M; Chen X; Ye K; Yao Y; Li Y
Medicine (Baltimore); 2016 Jun; 95(25):e3951. PubMed ID: 27336891
[TBL] [Abstract][Full Text] [Related]
7. Pathogen recognition and Toll-like receptor targeted therapeutics in innate immune cells.
Tartey S; Takeuchi O
Int Rev Immunol; 2017 Mar; 36(2):57-73. PubMed ID: 28060562
[TBL] [Abstract][Full Text] [Related]
8. Decoding Toll-like receptors: Recent insights and perspectives in innate immunity.
Kawai T; Ikegawa M; Ori D; Akira S
Immunity; 2024 Apr; 57(4):649-673. PubMed ID: 38599164
[TBL] [Abstract][Full Text] [Related]
9. Targeting Toll-Like Receptors for Cancer Therapy.
Braunstein MJ; Kucharczyk J; Adams S
Target Oncol; 2018 Oct; 13(5):583-598. PubMed ID: 30229471
[TBL] [Abstract][Full Text] [Related]
10. Important aspects of Toll-like receptors, ligands and their signaling pathways.
Chang ZL
Inflamm Res; 2010 Oct; 59(10):791-808. PubMed ID: 20593217
[TBL] [Abstract][Full Text] [Related]
11. Promising Targets for Cancer Immunotherapy: TLRs, RLRs, and STING-Mediated Innate Immune Pathways.
Li K; Qu S; Chen X; Wu Q; Shi M
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28216575
[TBL] [Abstract][Full Text] [Related]
12. Toll-like receptor-targeted particles: A paradigm to manipulate the tumor microenvironment for cancer immunotherapy.
Tran TH; Tran TTP; Truong DH; Nguyen HT; Pham TT; Yong CS; Kim JO
Acta Biomater; 2019 Aug; 94():82-96. PubMed ID: 31129358
[TBL] [Abstract][Full Text] [Related]
13. Toll-like receptors in breast cancer immunity and immunotherapy.
Zhou J; Zhang L; Liu S; DeRubeis D; Zhang D
Front Immunol; 2024; 15():1418025. PubMed ID: 38903515
[TBL] [Abstract][Full Text] [Related]
14. The Yin and Yang of Toll-like receptors in cancer.
Pradere JP; Dapito DH; Schwabe RF
Oncogene; 2014 Jul; 33(27):3485-95. PubMed ID: 23934186
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor signaling in parasitic infections.
Ashour DS
Expert Rev Clin Immunol; 2015 Jun; 11(6):771-80. PubMed ID: 25896399
[TBL] [Abstract][Full Text] [Related]
16. Recent Findings on the Application of Toll-like Receptors Agonists in Cancer Therapy.
Mikulandra M; Pavelic J; Glavan TM
Curr Med Chem; 2017; 24(19):2011-2032. PubMed ID: 28322156
[TBL] [Abstract][Full Text] [Related]
17. Toll-like receptors: Triggers of regulated cell death and promising targets for cancer therapy.
Yang Y; Feng R; Wang YZ; Sun HW; Zou QM; Li HB
Immunol Lett; 2020 Jul; 223():1-9. PubMed ID: 32311408
[TBL] [Abstract][Full Text] [Related]
18. RAGE and TLRs: relatives, friends or neighbours?
Ibrahim ZA; Armour CL; Phipps S; Sukkar MB
Mol Immunol; 2013 Dec; 56(4):739-44. PubMed ID: 23954397
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic targeting of toll-like receptors in gastrointestinal inflammation.
Ishihara S; Rumi MA; Ortega-Cava CF; Kazumori H; Kadowaki Y; Ishimura N; Kinoshita Y
Curr Pharm Des; 2006; 12(32):4215-28. PubMed ID: 17100624
[TBL] [Abstract][Full Text] [Related]
20. Activation of the innate immune system in atherosclerotic disease.
Oude Nijhuis MM; van Keulen JK; Pasterkamp G; Quax PH; de Kleijn DP
Curr Pharm Des; 2007; 13(10):983-94. PubMed ID: 17430162
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
